Chris Anselmo is a 32-year-old Connecticut resident who currently serves as a market intelligence manager on the Healthcare Partnerships team within the Muscular Dystrophy Association’s national office. In his role, Chris performs research on the neuromuscular disease drug development landscape and builds strategic relationships with the biotech and pharmaceutical industries and with other patient organizations.
Chris has a personal connection to MDA’s mission — he is also a patient living with Miyoshi myopathy/limb-girdle muscular dystrophy type 2B (LGMD2B), an adult-onset form of muscular dystrophy. For the first 21 years of his life, Chris had no signs of muscle weakness. Then one night in 2008, while going for a run, he noticed his legs tired out quickly. Over the next 11 years, Chris experienced progressive muscle weakness, numerous falls, and a gradual loss of mobility. It was a difficult transition — one that took many years to fully accept.
Today, Chris is a patient advocate who is passionate about raising awareness for rare diseases, educating healthcare stakeholders on the power of the patient experience, and helping anyone dealing with adversity — especially newly diagnosed patients navigating the ups and downs of a life-changing diagnosis.
Chris is an active writer and speaker. He has spoken at the NORD Breakthrough Summit, the Jain Foundation Research Conference, Spaulding Rehabilitation Hospital, UMass Medical Center, and to student audiences at Northeastern University and Boston College. His writing credits include STAT News, Life Science Leader Magazine, The Hartford Courant, and WBUR’s CommonHealth.
Chris holds an MBA from Boston College and a bachelor’s degree in marketing from Northeastern University.
118B, Level 100